Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2011 (2011), Article ID 564321, 7 pages
http://dx.doi.org/10.4061/2011/564321
Review Article

Biomarkers of the Dementia

Department of Neurology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, Aomori 036-8216, Japan

Received 20 January 2011; Accepted 30 March 2011

Academic Editor: Katsuya Urakami

Copyright © 2011 Mikio Shoji. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Petersen, P. S. Aisen, L. A. Beckett et al., “Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization,” Neurology, vol. 74, no. 3, pp. 201–209, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. Shoji and M. Kanai, “Cerebrospinal fluid Aβ40 and Aβ42: natural course and clinical usefulness,” Journal of Alzheimer's Disease, vol. 3, no. 3, pp. 313–321, 2001. View at Google Scholar
  3. M. Shoji, M. Kanai, E. Matsubara et al., “The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently,” Neurobiology of Aging, vol. 22, no. 2, pp. 209–215, 2001. View at Publisher · View at Google Scholar
  4. M. Kanai, E. Matsubara, K. Isoe et al., “Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan,” Annals of Neurology, vol. 44, no. 1, pp. 17–26, 1998. View at Publisher · View at Google Scholar · View at PubMed
  5. J. E. Kang, M. M. Lim, R. J. Bateman et al., “Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle,” Science, vol. 326, no. 5955, pp. 1005–1007, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. Shoji, T. E. Golde, J. Ghiso et al., “Production of the Alzheimer amyloid β protein by normal proteolytic processing,” Science, vol. 258, no. 5079, pp. 126–129, 1992. View at Google Scholar · View at Scopus
  7. R. J. Bateman, E. R. Siemers, K. G. Mawuenyega et al., “A γ-secretase inhibitor decreases amyloid-β production in the central nervous system,” Annals of Neurology, vol. 66, no. 1, pp. 48–54, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. Shoji, E. Matsubara, T. Murakami et al., “Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group,” Neurobiology of Aging, vol. 23, no. 3, pp. 363–370, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Suzuki, T. T. Cheung, X. D. Cai et al., “An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP) mutants,” Science, vol. 264, no. 5163, pp. 1336–1340, 1994. View at Google Scholar · View at Scopus
  10. M. Shoji, M. Kanai, E. Matsubara et al., “Taps to Alzheimer's patients: a continuous Japanese study of cerebrospinal fluid biomarkers [5],” Annals of Neurology, vol. 48, no. 3, p. 402, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Hulstaert, K. Blennow, A. Ivanoiu et al., “Improved discrimination of AD patients using β-amyloid((1-42)) and tau levels in CSF,” Neurology, vol. 52, no. 8, pp. 1555–1562, 1999. View at Google Scholar · View at Scopus
  12. D. S. Knopman, S. T. DeKosky, J. L. Cummings et al., “Practice parameter: diagnosis of dementia (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology,” Neurology, vol. 56, no. 9, pp. 1143–1153, 2001. View at Google Scholar · View at Scopus
  13. N. Andreasen, L. Minthon, P. Davidsson et al., “Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice,” Archives of Neurology, vol. 58, no. 3, pp. 373–379, 2001. View at Google Scholar · View at Scopus
  14. C. M. Clark, S. Xie, J. Chittams et al., “Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?” Archives of Neurology, vol. 60, no. 12, pp. 1696–1702, 2003. View at Publisher · View at Google Scholar · View at PubMed
  15. T. Sunderland, G. Linker, N. Mirza et al., “Decreased β-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease,” Journal of the American Medical Association, vol. 289, no. 16, pp. 2094–2103, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. N. Itoh, H. Arai, K. Urakami et al., “Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease,” Annals of Neurology, vol. 50, no. 2, pp. 150–156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Hampel, K. Buerger, R. Zinkowski et al., “Measurement of phosphorylated tau epitopes in the differential diagnosis of alzheimer disease: a comparative cerebrospinal fluid study,” Archives of General Psychiatry, vol. 61, no. 1, pp. 95–102, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. K. Blennow and H. Hampel, “CSF markers for incipient Alzheimer's disease,” Lancet Neurology, vol. 2, no. 10, pp. 605–613, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Hampel, S. J. Teipel, T. Fuchsberger et al., “Value of CSF β-amyloid and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment,” Molecular Psychiatry, vol. 9, no. 7, pp. 705–710, 2004. View at Google Scholar · View at Scopus
  20. L. Parnetti, A. Lanari, G. Silvestrelli, E. Saggese, and P. Reboldi, “Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers,” Mechanisms of Ageing and Development, vol. 127, no. 2, pp. 129–132, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study,” Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006. View at Publisher · View at Google Scholar · View at PubMed
  22. A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris, and D. M. Holtzman, “Cerebrospinal fluid tau/β-amyloid ratio as a prediction of cognitive decline in nondemented older adults,” Archives of Neurology, vol. 64, no. 3, pp. 343–349, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. L. M. Shaw, H. Vanderstichele, M. Knapik-Czajka et al., “Cerebrospinal fluid biomarker signature in alzheimer's disease neuroimaging initiative subjects,” Annals of Neurology, vol. 65, no. 4, pp. 403–413, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. J. Q. Trojanowski, H. Vandeerstichele, M. Korecka et al., “Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects,” Alzheimer's and Dementia, vol. 6, no. 3, pp. 230–238, 2010. View at Publisher · View at Google Scholar · View at PubMed
  25. L. G. Apostolova, K. S. Hwang, J. P. Andrawis et al., “3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects,” Neurobiology of Aging, vol. 31, no. 8, pp. 1284–1303, 2010. View at Publisher · View at Google Scholar · View at PubMed
  26. J. Nettiksimmons, D. Harvey, J. Brewer et al., “Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline,” Neurobiology of Aging, vol. 31, no. 8, pp. 1419–1428, 2010. View at Publisher · View at Google Scholar · View at PubMed
  27. O. C. Okonkwo, M. L. Alosco, H. R. Griffith et al., “Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease,” Archives of Neurology, vol. 67, no. 6, pp. 688–696, 2010. View at Publisher · View at Google Scholar · View at PubMed
  28. N. Mattsson, H. Zetterberg, O. Hansson et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. P. J. Visser, F. Verhey, D. L. Knol et al., “Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study,” The Lancet Neurology, vol. 8, no. 7, pp. 619–627, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Matsubara, J. Ghiso, B. Frangione et al., “Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome,” Annals of Neurology, vol. 45, no. 4, pp. 537–541, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. M. van Oijen, A. Hofman, H. D. Soares, P. J. Koudstaal, and M. M. Breteler, “Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a prospective case-cohort study,” Lancet Neurology, vol. 5, no. 8, pp. 655–660, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. N. R. Graff-Radford, J. E. Crook, J. Lucas et al., “Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease,” Archives of Neurology, vol. 64, no. 3, pp. 354–362, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. N. Schupf, M. X. Tang, H. Fukuyama et al., “Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 37, pp. 14052–14057, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. W. Xu, T. Kawarabayashi, E. Matsubara et al., “Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls,” Brain Research, vol. 1219, pp. 169–179, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. J. C. Lambert, S. Schraen-Maschke, F. Richard et al., “Association of plasma amyloid β with risk of dementia: the prospective Three-City Study,” Neurology, vol. 73, no. 11, pp. 847–853, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. O. I. Okereke, W. Xia, D. J. Selkoe, and F. Grodstein, “Ten-year change in plasma amyloid β levels and late-life cognitive decline,” Archives of Neurology, vol. 66, no. 10, pp. 1247–1253, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. W. Xia, T. Yang, G. Shankar et al., “A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease,” Archives of Neurology, vol. 66, no. 2, pp. 190–199, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. M. Noguchi-Shinohara, T. Tokuda, M. Yoshita et al., “CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease,” Brain Research, vol. 1251, pp. 1–6, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. Z. Hong, M. Shi, K. A. Chung et al., “DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease,” Brain, vol. 133, no. 3, pp. 713–726, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. T. Kasai, T. Tokuda, N. Ishigami et al., “Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis,” Acta Neuropathologica, vol. 117, no. 1, pp. 55–62, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus